Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 1/20 | 0.53 |
| ▸ | AURKA | O14965 | 3/20 | 0.49 |
| ▸ | S100A4 | P26447 | 2/20 | 0.49 |
| ▸ | KDR | P35968 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | PTPRC | P08575 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
| ▸ | PARP1 | P09874 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4718488 | 0.83 | ACHE (0.50) | ACHES100A4KMT2AMAPTRECQL | |
| SCHEMBL27456802 | 0.81 | ACHE (0.47) | ACHES100A4KMT2AMAPTRECQL | |
| SCHEMBL4694280 | 0.77 | TDP2 (0.59) | ACHES100A4KMT2AMAPTRECQL | |
| SCHEMBL2060410 | 0.75 | S100A4 (0.47) | ACHES100A4KMT2AMAPTRECQL | |
| SCHEMBL28381941 | 0.74 | ACHE (0.58) | ACHES100A4KDRKMT2AMAPT | |
| SCHEMBL30740520 | 0.73 | MAPT (0.66) | ACHES100A4KMT2AMAPTRECQL | |
| SCHEMBL869059 | 0.72 | CDK5 (0.54) | S100A4KDRKMT2AMAPTRECQL | |
| SCHEMBL31316525 | 0.72 | CDK5 (0.54) | S100A4KDRKMT2AMAPTRECQL | |
| SCHEMBL3039191 | 0.72 | TDP1 (0.67) | ACHES100A4KMT2AMAPTRECQL | |
| SCHEMBL4621603 | 0.71 | ACHE (0.56) | ACHES100A4KMT2AMAPTRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | claimed |
| CN-117088905-A | Asymmetric boron-fluorine pyrrole fluorescent dye, preparation method thereof and method for preparing fluorescent microspheres | 南京珀立科技有限公司 | 2023-11-21 | — | — | CN | claimed |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | DONG-A ST CO., LTD. (KR) | 2025-03-04 | — | — | US | disclosed |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | DONG-A ST CO., LTD. (KR) | 2024-01-25 | — | — | US | disclosed |
| CN-117088905-A | Asymmetric boron-fluorine pyrrole fluorescent dye, preparation method thereof and method for preparing fluorescent microspheres | 南京珀立科技有限公司 | 2023-11-21 | — | — | CN | disclosed |
| US-20230227484-A1 | PYRIMIDINE COMPOUND AS AXL INHIBITOR | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2023-07-20 | — | — | US | disclosed |
| US-20230227484-A1 | PYRIMIDINE COMPOUND AS AXL INHIBITOR | NANJING CHIA TAI TIANQING PHARMACEUTICAL CO., LTD. (CN) | 2023-07-20 | — | — | US | disclosed |
| EP-4163278-A1 | PYRIMIDINE COMPOUND AS AXL INHIBITOR | Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd. (CN) | 2023-04-12 | — | — | EP | disclosed |
| CN-106957299-A | A kind of lenalidomide preparation method | 常州制药厂有限公司 | 2017-07-18 | — | — | CN | disclosed |
| EP-1781640-B1 | 2,4-DI(AMINOPHENYL)PYRIMIDINE DERIVATIVES AS PLK INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2015-01-07 | — | — | EP | disclosed |
| EP-2486012-B1 | PROCESSES FOR THE PREPARATION OF 2-(1-PHENYLETHYL) ISOINDOLIN-1-ONE COMPOUNDS | CELGENE CORP (US) | 2013-12-11 | — | — | EP | disclosed |
| CN-101495450-A | Isoindole derivatives useful for treating pain, gastrointestinal diseases and cancer | ASTRAZENECA AB (SE) | 2009-07-29 | — | — | CN | disclosed |
| US-20090163465-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-11 | — | — | US | disclosed |
| US-7521457-B2 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-21 | — | — | US | disclosed |
| EP-1781640-A1 | 2,4-DI(AMINOPHENYL)PYRIMIDINE DERIVATIVES AS PLK INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2007-05-09 | — | — | EP | disclosed |
| US-20060148800-A1 | Pyrimidines as PLK inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-07-06 | — | — | US | disclosed |
| WO-2006021544-A1 | 2,4-DI(AMINOPHENYL) PYRIMIDINES AS PLK INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-03-02 | — | — | WO | disclosed |
| EP-0686625-B1 | ANTHRANILIC ACID DERIVATIVE | EISAI CO LTD (JP) | 1999-05-26 | — | — | EP | disclosed |
| US-5716993-A | PHOSPHODIESTERASE ENZYME INHIBITOR FOR TREATING CARDIOVASCULAR DISORDER, ANGINA PECTORIS, HYPERTENSION, ASTHMA | EISAI CO., LTD. (JP) | 1998-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163465-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | ACHE 2878/4885AURKA 90/4885S100A4 4474/4885 |
| US-20090149438-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | ACHE 2878/4885AURKA 90/4885S100A4 4474/4885 |
| US-12240836-B2 | Compounds as GCN2 inhibitors, pharmaceutical compositions and uses thereof | EIF2AK4, GCN1, GCGR | ACHE 4586/4885AURKA 4571/4885S100A4 3678/4885 |
| US-20230227484-A1 | PYRIMIDINE COMPOUND AS AXL INHIBITOR | AXL, FLT3, TYMP | ACHE 3707/4885AURKA 66/4885S100A4 4140/4885 |
| US-20240025884-A1 | COMPOUNDS AS GCN2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | EIF2AK4, GCN1, GCGR | ACHE 4586/4885AURKA 4571/4885S100A4 3678/4885 |
| US-20060148800-A1 | Pyrimidines as PLK inhibitors | PLK2, PLK3, TYMP | ACHE 2878/4885AURKA 90/4885S100A4 4474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.